Results 41 to 50 of about 14,154 (120)
Thymic Involution and Function in People With HIV and General Population Controls: A Cross‐Sectional Analysis From Two Danish Cohort Studies
Aging Cell, Volume 25, Issue 10, October 2026.Thymic involution, the age‐related replacement of thymic soft tissue by fat, has been linked to immunosenescence and chronic inflammation. Whether HIV infection affects thymic involution remains unclear. We found that people with HIV on long‐term antiretroviral therapy had more thymic tissue than controls, indicating less thymic involution. More thymic Manon C. Vanbellinghen, Anders Boyd, Andreas Ohrt Johansen, Moises Alberto Suarez‐Zdunek, Andreas Dehlbæk Knudsen, Thomas Skårup Kristensen, Jørgen Tobias Kühl, Per Ejlstrup Sigvardsen, Michael Huy Cuong Pham, Andreas Fuchs Larsen, Klaus Fuglsang Kofoed, Børge Grønne Nordestgaard, Shoaib Afzal, Neeltje Kootstra, Susanne Dam Nielsen, Peter Reiss +15 morewiley +1 more sourceUltRaSoUnd‐guided evaLuAtion of metabolic health in a cohort of midlife women with HIV: The URSULA study
HIV Medicine, Volume 27, Issue 10, Page 1650-1662, October 2026.Abstract Objectives
We aimed to determine the prevalence of metabolic disorders, liver steatosis and metabolic dysfunction‐associated steatotic liver disease (MASLD) in a cohort of middle‐aged women with HIV (WoWH) and to explore associations between liver steatosis, visceral fat depots and carotid atherosclerosis.Mariacristina Poliseno, Davide Capruzzi, Antonio Cianciaruso, Nicola Colavito, Felicia Dalitto, Vincenzo Giliberti, Vittoria Lobalsamo, Giuliana Metrangolo, Marica Noviello, Alessandra Vigna, Maurizio Zarcone, Francesco Di Gennaro, Vincenzo Ostilio Palmieri, Annalisa Saracino +13 morewiley +1 more sourceThe comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study [PDF]
, 2018 BACKGROUND
Nucleoside (or nucleotide) reverse transcriptase inhibitors (NRTIs) cause side effects in some patients, prompting the use of either partly or fully NRTI-sparing regimens.
METHODS
We used data from the Swiss HIV Cohort Study to estimate the Swiss HIV Cohort Study, Calmy, A., Hachfeld, Anna, Günthard, Huldrych F, Young, Jim, Tarr, Philip E, Young, J., Cavassini, M., Scherrer, A.U., Günthard, H.F., Scherrer, Alexandra U, Vernazza, P., Vernazza, Pietro, Hachfeld, A., Bucher, H.C., Tarr, P.E., Calmy, Alexandra, Bucher, Heiner C, Bernasconi, Enos, Cavassini, Matthias, Bernasconi, E., Vernazza P, Hachfeld A, Calmy A, Cavassini M, Tarr PE, Bucher HC, Günthard HF, Scherrer AU, Young J, Bernasconi E, Enos Bernasconi, Alexandra U Scherrer, Pietro Vernazza, Jim Young, Heiner C Bucher, Alexandra Calmy, Philip E Tarr, null null, Huldrych F Günthard, Matthias Cavassini, Anna Hachfeld +41 morecore +1 more sourceHealth transitions in HIV-seropositive individulas undergoing NRTI-based and NRTI-sparing treatment strategies.
, 2015 NRTI-sparing strategies are often prescribed to reduce the impact of drug toxicities on age related co-morbidities, particularly relevant in frail individuals.STENTARELLI, Chiara, ZONA, Stefano, MUSSINI, Cristina, GUARALDI, Giovanni, MALAGOLI, Andrea +4 morecore Prevalence of major NRTI and NNRTI resistance mutations in individuals with transmitted drug resistance.
, 2016 Absolute and cumulative prevalence of each major nucleoside (NRTI) and nonnucleoside RT Inhibitor (NNRTI) drug-resistance mutation (DRM) in individuals with intermediate or high-level transmitted NRTI or NNRTI resistance from a meta-analysis of 287 ...Neil Parkin (273844), Annemarie M. J. Wensing (105565), Rami Kantor (7863), Soo-Yon Rhee (42412), Elliot Raizes (840995), Mark A. Wainberg (196455), Irene Mukui (757883), Douglas D. Richman (168764), Mina C. Hosseinipour (143744), Jonathan M. Schapiro (374093), Joseph E. Fitzgibbon (840997), Marco Schito (840998), Carole L. Wallis (326872), Nicaise Ndembi (703630), Michael R. Jordan (146520), Raph L. Hamers (718072), Avelin F. Aghokeng (322582), Clement Zeh (226174), Gert U. Van Zyl (427181), Michele Tang (840996), Robert W. Shafer (32534), Tobias F. Rinke de Wit (178193), Joseph Fokam (322576), Lisa M. Frenkel (337077), Chunfu Yang (293864), Arlene Chua (134856), Joel E. Gallant (348304), David Katzenstein (182035), Silvia Bertagnolio (57174), Ravindra K. Gupta (372679), Tulio De Oliveira (5666317), Sergio Carmona (562195) +31 morecore +1 more sourceDistribution of NRTI (a) and NNRTI (b) resistance-associated mutations detected in the historical genotypic resistance tests of the patients.
, 2015 NNRTI: non nucleoside reverse transcriptase inhibitors, NRTI: nucleoside reverse transcriptase inhibitors.Benoit Visseaux (288245), Diane Descamps (266281), Gilles Peytavin (317457), Minh Patrick Lê (777286), Charlotte Charpentier (49588), Roland Landman (391389), Patrick Yéni (5664625), Sylvie Lariven (777287), Véronique Joly (301541), Yazdan Yazdanpanah (237840), Bao Phung (777288) +10 morecore +1 more sourceNucleoside/tide Reverse Transcriptase Inhibitor (NRTI) mutation profiles.
, 2014 Nucleoside/tide Reverse Transcriptase Inhibitor (NRTI) mutation profiles associated with failure to d4T- or ABC -based regimens are depicted in white and grey respectively. The numbers represent percentages.Irene Ketseoglou (562194), Michelle Bronze (326869), Kim Steegen (326871), Leon Levin (562193), Maria A. Papathanasopoulos (326877), Sergio Carmona (562195), Wendy Stevens (62288) +6 morecore +1 more sourceDrug resistance mutations to NRTI, NNRTI and PI according to the HIV-1 subtypes and resistance profile.
, 2019 Drug resistance mutations to NRTI, NNRTI and PI according to the HIV-1 subtypes and resistance profile.Marinela Mirandela (8044202), Domingos Jandondo (8044205), Miguel Brito (3585407), Joana Morais (8044211), Carlos S. de Jesus (8044199), José C. Couto-Fernandez (8044208), Cruz S. Sebastião (8044193), Amilcar Tanuri (7885), Zoraima Neto (8044196) +8 morecore +1 more source